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Background: Cardiac resynchronization therapy (CRT) is an established treatment in heart failure patients. However,
a large proportion of patients remain nonresponsive to this pacing strategy. Left ventricular (LV) lead position is one
of the main determinants of response to CRT. This study aims to clarify whether multimodality imaging guided LV
lead placement improves clinical outcome after CRT.
Methods/Design: The ImagingCRT study is a prospective, randomized, patient- and assessor-blinded, two-armed
trial. The study is designed to investigate the effect of imaging guided left ventricular lead positioning on a clinical
composite primary endpoint comprising all-cause mortality, hospitalization for heart failure, or unchanged or
worsened functional capacity (no improvement in New York Heart Association class and <10% improvement in
six-minute-walk test). Imaging guided LV lead positioning is targeted to the latest activated non-scarred myocardial
region by speckle tracking echocardiography, single-photon emission computed tomography, and cardiac
computed tomography. Secondary endpoints include changes in LV dimensions, ejection fraction and
dyssynchrony. A total of 192 patients are included in the study.
Discussion: Despite tremendous advances in knowledge with CRT, the proportion of patients not responding to
this treatment has remained stable since the introduction of CRT. ImagingCRT is a prospective, randomized study
assessing the clinical and echocardiographic effect of multimodality imaging guided LV lead placement in CRT. The
results are expected to make an important contribution in the pursuit of increasing response rate to CRT.
Trial registration: Clinicaltrials.gov identifier NCT01323686. The trial was registered March 25, 2011 and the first
study subject was randomized April 11, 2011.
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Cardiac resynchronization therapy (CRT) is an estab-
lished treatment in symptomatic heart failure patients
with depressed left ventricular (LV) ejection fraction
(EF) and prolonged QRS duration [1-5]. The therapy is
implemented by implanting a device with three pacing
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reproduction in any medium, provided the orand one in a LV epicardial vein) that uses atrial-
synchronized biventricular pacing to coordinate RV and
LV contraction. Despite technical advances and increas-
ing experience in CRT, approximately 30 to 50% of pa-
tients derive no clinical benefit from this treatment
[1,2,4]. An important determinant of response to CRT is
selection of the LV pacing site [6,7]. Currently, the LV
lead is preferably placed in a lateral or postero-lateral
branch of the coronary sinus (CS) [8]. Retrospective
studies have shown superior clinical and echocardio-
graphic outcome when placing the LV lead in a regionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Randomization - stratified according to presence or absence 
of coronary artery disease
Assessment of eligibility
Baseline evaluation and multimodality imaging including 
speckle tracking echocardiography, SPECT, and cardiac CT
Pre-discharge pacemaker test and
echocardiographic AV and VV optimization
Empiric LV lead 
placement
Imaging guided LV lead 
placement
One month pacemaker test and
echocardiographic AV and VV optimization
Six months follow-up including echocardiography and 
cardiac CT
Figure 1 Study design. Flow chart describing the ImagingCRT
study design. Randomization is stratified according to presence or
absence of coronary artery disease. AV, atrioventricular; CT,
computed tomography; LV, left ventricle; SPECT, single-photon
emission computed tomography; VV, interventricular.
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the latest mechanical activation [6-13]. Assessment of
the latest activated LV myocardial segment, scar areas
and cardiac venous anatomy can be performed by
speckle tracking echocardiography, single-photon emis-
sion computed tomography (SPECT), and cardiac
computed tomography (CT), respectively [7,9,12,14,15].
Promising results on CRT outcome have been reported
in recent prospective studies evaluating the effect of
echocardiography guided LV lead placement [16,17].
To clarify the potential role of imaging guided LV lead
positioning we have designed a prospective, patient- and
assessor-blinded, randomized trial comparing empiric
versus multimodality imaging guided LV lead placement
on clinical outcome after CRT. The main objective of
this study is to determine the effect of imaging guided
LV lead placement (targeted to the latest activated
non-scarred myocardial region by speckle tracking echo-
cardiography, SPECT and cardiac CT) on clinical
response rate to CRT.
Methods
Study design
The ImagingCRT study is a prospective, patient- and
assessor-blinded, randomized, single center trial with
two study arms. Echocardiography, SPECT and cardiac
CT is performed in all study participants. Subsequently,
patients are randomly assigned to standard LV place-
ment preferably in a lateral or posterior-lateral position
or LV lead positioning guided by multimodality imaging
to the latest mechanically activated non-scarred myocar-
dial region. Patients are allocated 1:1 to each interven-
tion arm and followed for six months (Figure 1). A total
of 192 patients will be enrolled in the study.
Study population
Study subjects are recruited at a tertiary referral center
(Department of Cardiology, Aarhus University Hospital,
Skejby, Denmark). Study enrollment criteria are listed in
Table 1. Patients receiving a CRT pacemaker (CRT-P) or
a CRT-implantable cardioverter defibrillator (CRT-D)
device are eligible for enrollment. Patients undergoing
upgrade from a single-lead or dual-chamber pacemaker
or implantable cardioverter-defibrillator can be included.
Reasons for excluding patients are recorded.
Ethical considerations
The study conforms to the principles outlined in the
Declaration of Helsinki [18]. The Central Denmark re-
gional committee on health research ethics (file no.
20100245) and the Danish Data Protection Agency (file
no. 2011-41-6017) have approved the study protocol. Pa-
tients participate in the study only after giving informed
written consent.Data collection and recordings
All study data are recorded in a web based case record
form (eCRF) with logging of all data entries. All investi-
gators have access to the eCRF.
Assessment of study variables
Baseline clinical and functional evaluation
Medical records are assessed. Functional capacity is eval-
uated using the six-minute-walk test (6MWT) [19] and
the New York Heart Association (NYHA) classification
[20]. Quality of life is assessed by the Minnesota Living
with Heart Failure Questionaire, a 21-item disease spe-
cific instrument with scores varying from 0 to 5 and a
summary score varying from 0 to 105, the highest score
representing the worst health-related quality of life.
Table 1 Study enrollment criteria
Inclusion criteria Exclusion criteria
• NYHA functional class II to IV despite optimal medical treatment • Recent myocardial infarction (<3 months)
• ECG with QRS >120 ms and LBBB configuration or paced QRS >180 ms • Expected lifetime <6 months
• LV EF ≤35% • Pregnant or lactating
• Age >40 years • Inadequate echocardiographic images for determination of site
with latest mechanical activation
• Written informed consent • No written informed consent
Inclusion/exclusion criteria. LBBB: left bundle branch block; LV EF: left ventricular ejection fraction; NYHA: New York Heart Association [20].
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Danish version exists [21-23].
Blood is drawn for laboratory test of renal function
and N-terminal pro b-type natriuretic peptide (NT-
ProBNP).Echocardiography
Baseline and follow-up echocardiographic images are
obtained at rest with a 3.5-MHz transducer using a com-
mercially available system (Vivid E9, GE Medical Sys-
tems, Horten, Norway). Two-dimensional (2D), color
Doppler and tissue Doppler imaging (TDI) data trig-
gered to the ECG are stored in cine-loop format and
transferred to a workstation for offline analysis using
dedicated software (EchoPac BT11, GE Medical Systems,
Horten, Norway). At least three consecutive beats are
recorded during breath hold in all views. All measure-
ments are averaged over three cycles.
LV end-diastolic volume (EDV) and end-systolic vol-
ume (ESV) are assessed from standard apical four- and
two-chamber views. LV EF is estimated using Simpson’s
biplane method [24]. Severity of mitral regurgitation is
graded semi-quantitatively [25].Figure 2 Speckle tracking radial strain analysis. Assessment of LV radia
two-dimensional speckle tracking radial strain imaging. Time-strain curves a
LV dyssynchrony with a 266 ms delay between the septal and posterior se
(yellow arrow). Ant, anterior; Ant-Sept, antero-septal; Inf, inferior; Lat, lateralLV dyssynchrony and latest activated myocardial region
LV dyssynchrony is evaluated using 2D speckle tracking
radial strain on mid-LV short axis views [26]. Images are
obtained with a frame rate of 50 to 80 s-1. Care is taken
to avoid oblique mid-LV short axis views and to obtain im-
ages with the most circular geometry. In an end-systolic
frame, the LV endocardial contour is traced. Subsequently,
the software automatically defines the region of interest
including the entire myocardial wall. Adequate tracking of
the region of interest throughout the cardiac cycle is en-
sured by visual control and, if necessary, optimized by
manual adjustment. Time-strain curves are generated for
the six mid-LV segments (antero-septal, anterior, lateral,
posterior, inferior and septal). Time from QRS onset to
peak radial strain is measured in all segments and the lat-
est activated segment is identified. LV dyssynchrony is
measured as time delay between the earliest and latest
activated segment (Figure 2) [27].
In a small minority of patients we expect that speckle
tracking is not feasible. In that case we use tissue
synchronization imaging with automated color-coding of
time to peak longitudinal velocities derived from TDI to
identify the mid-LV segment with latest activation
[11,15,28].l dyssynchrony and the latest mechanically activated segment by
re shown for the six mid-LV segments. This patient example illustrates
gment. Site of the latest mechanical activation is the posterior segment
; Post, posterior; Sept, septum.
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Rest 99mTc-sestamibi SPECT (700 ± 70 MBq) is performed
60 minutes after radiotracer injection using a dual-headed
rotating gamma camera (CardioMD, Phillips Healthcare,
Andover, MA, USA) with a high-resolution, parallel-holed
collimator. Sixty-four projections of 25 seconds are ac-
quired over a non-circular 180° arc. Images are gated with
eight frames per cardiac cycle. Analysis and reconstruction
of the acquired data are performed using commercially
available software (AUTOSPECT, AUTOQUANT; ADAC
Laboratories, Milpitas, CA, USA). In case of failure of the
automatic algorithm, manual tools for masking extra car-
diac activity or defining the valve plane and the apex of the
left ventricle are used. Data are displayed in polar map for-
mat (normalized to maximal tracer activity) and analyzed
using the 17-segment model (Figure 3) [29]. A tracer up-
take ≥75% is considered normal myocardium, 50 to 75%
tracer uptake is considered non-transmural scar tissue, and
an uptake <50% is considered transmural scar tissue [9].
Assessment of cardiac venous anatomy and LV lead
position
Cardiac CT is performed using a second-generation
dual-source CT system (Siemens Somatom Definition
Flash, Siemens Healthcare, Erlangen, Germany). Cardiac
CT is performed with 80 to 120 kV tube voltage, adap-
tive tube current with a reference of 370 mAs, 128 ×Figure 3 Left ventricular myocardial segmentation. The LV 17-
segment model used for SPECT interpretation. Basal and mid-LV
segments depicted in light gray are considered equal for LV lead
placement. Apical segments and apex are depicted in dark gray.
Numbers are in accordance with the clockwise method used for the
fluoroscopic venogram in the left anterior oblique projection. The
antero-lateral, infero-lateral and infero-septal segments correspond
to the echocardiographic lateral, posterior and septal segments,
respectively. Ant-Lat, antero-lateral; Inf-Lat, infero-lateral; Inf-Sept,
infero-septal; RV, right ventricle.0.6 mm collimation, z-flying spot and a gantry rotation
time of 280 msec. In retrospective scans an ECG-
controlled tube current modulation is applied with
reduction of the current to 20% and full pulsing applied
only from 60 to 70% of the RR interval. Retrospective
scan pitch is 0.2 to 0.4 depending on heart rate, and 3.4
for prospective scans, respectively. An iterative recon-
struction algorithm is applied (SAFIRE, Siemens Health-
care, Erlangen, Germany).
A two-step scan protocol is performed at baseline. An
ECG triggered test bolus is used to capture the CS with
regions of interest placed in the proximal CS and in the
LV cavity. During breath hold, image acquisition is
achieved in two consecutive steps. First, a retrospective
ECG-gated scan timed according to optimal contrast fill-
ing in the LV cavity. Subsequently, a prospective ECG-
gated high-pitch scan corresponding to optimal contrast
filling in the proximal CS. Commercially available con-
trast media (Optiray® 350 mg/ml, Covidien, Hazelwood,
MO, USA) is used (20 ml for the test bolus and 50 to
60 ml for the two-step scan). Contrast injection is
followed by a 50 ml saline flush. Images are analyzed
using commercially available software (Syngo.via and
Multimodality workplace, Siemens Healthcare, Erlangen,
Germany). The observer individually adjusts window set-
tings. For evaluation of cardiac venous anatomy, axial,
multiplanar reformats and three-dimensional (3D) im-
ages are reconstructed (Figure 4).
Six months after CRT implantation, a repeat retro-
spective contrast enhanced ECG-gated CT scan is
performed for evaluation of LV lead position (Figure 5).
In a small minority of patients with an allergy to con-
trast media or severely depressed renal function (esti-
mated glomerular filtration rate <30 ml/min) baseline
cardiac CT is omitted. Then, only the pre-implant coron-
ary venography is used for visualization of cardiac venous
anatomy and a non-contrast CT scan is performed for LV
lead localization at six months follow-up.
Optimal LV pacing site
The optimal LV pacing site is defined as the myocardial
region with the latest mechanical activation and without
transmural scar tissue. Basal and mid-LV segments in
the same LV wall are considered equally optimal
(Figure 3). Combining information from speckle tracking
echocardiography, SPECT and cardiac CT, imaging
guided LV lead placement is targeted to a vein at the
optimal pacing site. When two segments are equally
delayed, both segments are considered optimal for LV
pacing. If the latest activated segment has a SPECT
tracer uptake <50%, the second latest activated segment
is chosen as the optimal pacing site. CT images of car-
diac venous anatomy are assessed in 2D mid-LV short
axis views corresponding to a fluoroscopic left anterior
Figure 4 Evaluation of cardiac venous anatomy. Baseline cardiac
CT images from a prospective high pitch scan illustrating cardiac
venous anatomy in a chronic heart failure patient in the mid-LV
multiplanar reformatted short axis view (top) and in a three-
dimensional volume-rendered reconstruction (bottom). AIV, anterior
interventricular vein; CS, coronary sinus; CX, circumflex coronary
artery; LAD, left anterior descending artery; LMA, left marginal artery
(circumflex artery branch); LMV, left marginal vein; MCV, middle
cardiac vein; PDA, posterior descending artery (right coronary artery
branch); PV, posterior vein (PV and CX are not seen in the mid-LV
short axis view); RV, right ventricle.
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volume-rendered reconstructions (Figure 4). CS tributar-
ies closest to the optimal LV pacing site are labeled as
first priority for LV lead placement. Tributaries closest
to the second, third or fourth latest activated segment
with viable myocardium are chosen as second, third or
fourth priority, respectively. Images illustrating the latest
activated segment, the distribution of scar tissue, and
the prioritized CS tributaries are available to the
implanting physician only when the patient is random-
ized to imaging guided LV lead placement.
CRT implantation
All leads are implanted transvenously using commer-
cially available leads and devices. The right atrial lead is
placed in the right atrial appendage. In both CRT-P and
CRT-D implantations, the right ventricular lead is placed
on the interventricular septum or in the apex if a septal
position is not reached. CS venograms are obtained be-
fore implantation of the LV lead. In the LAO 40 to 60°
projection, the CS with its tributaries is seen encircling
the mitral valve ostium. During implantation the optimal
LV pacing site is located by the clockwise method in the
LV short-axis circumference [30]. According to the echo-
cardiographic LV short-axis view and the SPECT polar
map, the LV is divided into six equal segments from the
venogram in the LAO projection: Anterior-septal (9 to
11 o’clock), anterior (11 to 1 o’clock), lateral (1 to 3
o’clock), posterior (3 to 5 o’clock), inferior (5 to 7
o’clock), and septal (7 to 9 o’clock) (Figure 3). If the
patient is randomized to imaging guided LV lead place-
ment, the implanter aims to place the LV lead in the
vein closest to the optimal LV pacing site. If the primary
vein is not reached, the CS tributaries are aimed in pri-
oritized order until a stable position is reached with
acceptable thresholds below 2.5 V and with no phrenic
nerve stimulation at an output less than twice the
threshold. Empiric LV lead positioning is targeted to the
lateral or postero-lateral region, preferably in an area
with late electrical activation as measured online
(CardioLab IT, GE Healthcare, Waukesha, WI, USA).
Visualized in the right anterior oblique (RAO) 20 to 40°
view the LV lead is placed in a midventricular or basal
position avoiding apical segments.
Follow-up
The device is tested at day one, one month and six months
after implantation to ensure sufficient biventricular pacing
(>95% of the time). Atrioventricular (AV) and inter-
ventricular (VV) optimization is performed at day one and
repeated after one month. Optimal AV delay is obtained
by the iterative method using transmitral pulsed wave
Doppler to achieve the longest LV filling time with ad-
equate E- and A-wave separation and termination of the
Figure 5 Evaluation of LV lead position. Six months follow-up cardiac CT acquisition from the same patient as in Figure 4. In the mid-LV short
axis view, the LV lead is positioned in the left marginal vein draining the lateral LV wall (left). In the four-chamber view, the LV lead tip is
positioned in the lateral mid-LV segment (right). LA, left atrium; LAD, left anterior descending artery; LMA, left marginal artery (circumflex artery
branch); MCV, middle cardiac vein; PDA, posterior descending artery (right coronary artery branch); RA, right atrium; RV, right ventricle).
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the V-V sequence measuring the highest LV outflow tract
time-velocity integral [28].
At six months follow-up, clinical, functional and echo-
cardiographic variables are assessed as performed at
baseline. LV lead position is assessed by cardiac CT as
described and categorized as concordant (located at the
optimal LV pacing site), as adjacent (one segment away)
and remote (≥2 segments away from the optimal LV
pacing site).Endpoints
The primary endpoint is non-response to CRT defined
as the combination of all-cause mortality, hospitalization
for heart failure, and unchanged or worsened functional
status. The primary endpoint is attained if the patient is
registered for one of the following three events during
follow-up: (1) death from any cause, (2) hospitalization
for heart failure, or (3) no improvement in NYHA class
and <10% improvement in 6MWT.
Hospitalization for heart failure is defined as admis-
sion to the hospital lasting more than 24 hours with
symptoms of congestive heart failure and subsequent
intravenous treatment for heart failure.
Secondary endpoints include all-cause mortality,
hospitalization for heart failure and changes of the fol-
lowing variables during follow-up: NYHA class, 6MWT,
quality of life, Nt-ProBNP, LV EF, LV EDV and ESV, LV
dyssynchrony and mitral regurgitation grade. Also, pro-
cedure time for CRT implantation, ability to place the
LV lead in the first or second prioritized CS branch,
complications and final lead positions are recorded.Sample size
The study is designed to detect a clinically meaningful
difference between standard and imaging guided LV lead
positioning in CRT as measured by applying a clinical
composite endpoint. The underlying assumptions for the
primary endpoint are based on data from previous trials
in comparable patient cohorts demonstrating a 50 to
70% response rate to CRT [1,2,4,30]. Accordingly, we ex-
pect a 60% response rate in the group with empiric LV
lead placement and hypothesize an 80% response rate in
the group with imaging guided LV lead positioning.
Thus, we estimate a 20% difference in the percentage of
patients reaching the primary endpoint. To identify this
increase in response rate and to achieve a statistical
power of 80% a sample size of 182 patients is needed
(given a two-sided alpha value of 0.05). The sample
size calculation does not account for the stratified
randomization [31]. To compensate for an expected loss
of follow-up in approximately 5% of the patients, a total
of 192 patients are included. Sample size calculation was
performed using commercially available statistical soft-
ware (Stata version 12, StataCorp, College Station, TX,
USA) to estimate the sample size for a two-sample com-
parison of proportions.
Randomization and blinding procedure
Patients are randomized using a randomization module
in the eCRF. An external data manager is responsible for
the eCRF, including the randomization module. A ran-
dom allocation sequence is created using a standard
computerized random-number generator. Patients are
randomized in a permuted-block design employing dif-
ferent sized blocks. The randomization is stratified
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disease (≥50% stenosis of one or more major epicardial
arteries as revealed by a recent invasive coronary angiog-
raphy or medical records documenting a previous myo-
cardial infarction. Invasive coronary angiography is
performed before CRT implantation if no recent exam-
ination (within two years) is available). The stratified
randomization ensures a balance between treatment
groups with 50% of patients with coronary artery disease
in each group. Study subjects are allocated 1:1 to each
intervention arm. Physicians responsible for enrollment
of patients have no knowledge of block size or allocation
sequence. Information on randomization is available in
the implant window of the eCRF. Only the implanting
physician has access to this window. When the patient is
randomized to imaging guided LV lead placement the
implant window contains uploaded images illustrating
the LV region with the latest mechanical activation,
distribution of scar tissue, and cardiac venous anatomy,
respectively. When randomized to empiric LV lead
placement the implant window will not show these im-
ages; thus, the implanting physician does not have access
to information on LV mechanical activation pattern, dis-
tribution of scarred myocardium, and coronary venous
anatomy prior to CRT implantation.
All baseline and follow-up evaluations, including clin-
ical assessment, image acquisitions and analyses, are
blinded with respect to randomization. Patients are
blinded to the intervention arm. Randomization data
will be available when all patients have completed
follow-up.Statistical analysis
Demographic and baseline characteristics of both inter-
vention groups are presented and compared clinically.
At follow-up, a Pearson’s χ2 or Fisher’s exact test when
appropriate is used to compare categorical variables.
Normally distributed continuous variables are compared
using Student’s t-test. Continuous variables not normally
distributed are compared using a Wilcoxon’s rank-sum
test. Forty patients will be randomly selected for
assessing intra- and interobserver variability for the
dyssynchrony measurements using linear regression and
Bland-Altman analysis. In the same 40 patients, kappa
statistics are computed to assess intra- and interobserver
agreement of site with latest mechanical activation and
final LV lead position. All analyses will be conducted
according to the intention-to-treat principle. Multiple
imputation will be applied in case of missing data [32].
A two-sided P-value of <0.05 is considered to be statisti-
cally significant. Statistical software (Stata version 12,
StataCorp, College Station, TX, USA) is used for statis-
tical analysis.Discussion
The introduction of CRT has improved the treatment of
heart failure patients [1-4]. However, 30 to 50% of patients
continue to remain non-responsive to this pacing strategy
[1,2,4]. Optimal placement of the LV pacing lead has been
shown to be a crucial determinant of CRT response [6-8].
The ImagingCRT study is a randomized trial designed to
test the hypothesis that multimodality imaging guided LV
lead positioning can increase the response rate to CRT as
compared with standard LV lead placement.
Several retrospective echocardiographic studies using
speckle tracking demonstrated greater reverse LV re-
modeling and superior long-term prognosis in patients
with LV pacing concordant to the site of latest mechan-
ical activation when compared to patients with discord-
ance between LV lead position and the area with latest
activation [7,10,26]. Accordingly, in this study, assess-
ment of the latest mechanically activated LV segment is
performed using speckle tracking 2D radial strain.
Recent studies used speckle tracking low-amplitude
LV radial strain as a surrogate measure of myocardial
scar to demonstrate a poor CRT response when the LV
lead was placed in regions with low-amplitude radial
strain [7,33]. A 2012 assessor-blinded, prospective ran-
domized study found increased response rate to CRT
using speckle tracking radial strain to assess the site of
latest activation and as a measure of scar to guide LV
lead placement as compared to standard therapy [16].
However, low-amplitude radial strain may also occur in
non-ischemic heart failure patients with dilated LVs
without myocardial scar [34]. Retrospective magnetic
resonance imaging (MRI) and SPECT studies have dem-
onstrated an unfavorable outcome after CRT when the
LV lead is positioned in areas with transmural myocar-
dial scar [6,9,12]. Myocardial scar quantification by
SPECT is well validated in the literature and a practical
approach for current clinical practice [14]. Consequently,
SPECT imaging is performed for localization of myocar-
dial scar in the current study. The LV 17-segment model
is used for optimal agreement with echocardiography
and cardiac CT [29].
Visualization of cardiac venous anatomy by cardiac
CT is feasible and comparable to venography [15]. Car-
diac CT can reveal the presence of specific CS tributaries
and provide information on vessel course, side branches
and diameters prior to CRT implantation. Thus, cardiac
CT may further facilitate LV lead positioning to the opti-
mal pacing site. Therefore, in this study, a cardiac CT is
performed prior to CRT implantation.
Prior studies evaluating the effect of LV lead position on
outcome after CRT have used post-implantation chest
radiography, some combined with fluoroscopy, to deter-
mine final LV lead position [7,9,10,16,33]. However, chest
radiography and fluoroscopy are poor predictors of LV lead
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apply cardiac CT for assessment of LV lead position.
The criteria for response to CRT used in both pro-
spective and retrospective studies investigating the effect
of LV lead placement have been variable and often lim-
ited to changes in LV systolic dimension [7,10,16]. In
contrast, we apply a robust composite endpoint combin-
ing subjective and objective derived measurements
representing a global assessment of the patient [37].
Limitations
We acknowledge the inherent limitations of the single-
center study design. Nevertheless, this is a relatively
large prospective, patient- and assessor-blinded, random-
ized study evaluating the effect of multimodality imaging
guided LV lead placement on the response rate to CRT.
We do not merge the different imaging modalities. How-
ever, visualization of CS tributaries by cardiac CT can easily
be related to the clockwise method for fluoroscopic CS
visualization, which, again, may be correlated to the LV seg-
mentation used for myocardial SPECT and echocardiog-
raphy, respectively. Another limitation is the lower spatial
resolution of scar quantification by SPECT as compared to
MRI. However, a substantial minority of our patients is not
eligible for MRI because of an indwelling device.
Because of the radiation exposure associated with, for
example, cardiac CT and SPECT, there has been much
scrutiny on the increasing use of diagnostic cardiac im-
aging [38]. Several approaches to minimize radiation
dose are applied in this study, including the use of itera-
tive reconstruction algorithms, application of prospect-
ively triggered high pitch CT scan, individual settings of
tube voltage and current, tube current modulation with
narrow full current window, and the use of 99mTc-agents
in SPECT, respectively [39]. However, the introduction of
cardiac CT and SPECT into the diagnostic algorithm prior
to CRT will increase the cumulative radiation exposure of
patients. In the age group investigated in this study,
however, the stochastic risk of radiation-induced cancer
may likely be outweighed by the potential benefit of
multimodality imaging guided LV lead placement in CRT.
Perspective
Despite tremendous advances in knowledge and experi-
ence with CRT, the proportion of patients considered
clinical non-responders have remained stable since the
introduction of CRT. The effect of imaging guided LV
lead placement on CRT response rate, as tested in this
study, can make an important contribution in the pur-
suit of increasing response rate to CRT.
Trial status
The trial is ongoing. The first patient was randomized
on 11 April 2011. As of August 2012, 88 subjects hadbeen included. Enrollment completion is expected by
September 2013.
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